Biology Is Biography · Essay 2

MD Explains: Is Hormone Replacement Therapy Actually Dangerous, or Were Women Lied To for Twenty Years?

A Board-Certified Physician Breaks Down What the Evidence Really Shows. Hint: The Answer Isn’t “Good” or “Bad.”

Hormone Replacement Therapy: A nuanced look at risk, age, and evidence beyond the 2002 headlines. Source: Image concept by author created with help of AI.

A patient apologized to me last month before she’d even finished her sentence.

“I know this probably isn’t safe,” she said, “but I can’t sleep, and I’m tired of pretending I’m fine.”

She was talking about hormone therapy.

I hear a version of that apology constantly.

Women in their late forties and fifties, exhausted, quietly convinced that wanting relief from menopause symptoms makes them reckless. Somewhere in the last twenty years, a study most of them have never read became a permanent warning label in the back of their minds.

That study was real. The warning it produced wasn’t wrong, exactly. But it was applied far more broadly, and for far longer, than the evidence ever supported.

As a physician who has spent two decades watching patients navigate this exact fear, I’ve watched the pendulum swing from over-prescription in the 1990s, to near-total avoidance in the 2000s, and now toward a more accurate middle ground that most people still haven’t heard about.

So is hormone therapy actually dangerous?

The answer isn’t as simple as “good” or “bad.”

It depends on your age when you start, which hormones and formulations you use, and how long you stay on them. Let’s walk through what the evidence actually says — and what it means for you.

Why “Is Hormone Therapy Good or Bad?” Is the Wrong Question

Binary questions flatten twenty years of research into a single verdict. Hormone therapy was never one thing.

The formulation matters enormously.

Oral conjugated equine estrogen combined with a synthetic progestin behaves differently in the body than transdermal estradiol combined with bioidentical micronized progesterone — different clotting risk, different breast tissue response, different cardiovascular profile. Treating them as interchangeable is like treating aspirin and morphine as the same because both relieve pain.

Timing matters just as much.

Starting hormone therapy within ten years of menopause produces a different risk profile than starting it in your late sixties or seventies, a decade or more after your last period. The tissue you’re treating is not the same tissue at both ages.

And there’s a category of symptom that standard labs don’t capture at all.

Relative progesterone deficiency in perimenopause, which can disrupt sleep architecture years before estrogen has meaningfully declined. This is not a rare presentation. It is one of the most common things I see in women in their forties, and the standard hormone panel — the one that reassures a patient she’s “not in menopause yet” — misses it completely.

I described this pattern once through a patient I’ll call Meera.

Forty-four, exhausted, with five years of technically normal labs — a normal TSH, a normal fasting glucose, a lipid panel nobody flagged. Her estradiol read normal-to-high. What nobody had checked was her progesterone relative to her estrogen — the specific pattern that precedes measurable estrogen decline in perimenopause. She wasn’t having trouble falling asleep. She was failing to reach slow-wave sleep, the deep restorative stage her body needed to repair itself overnight, and no one had asked the question that would have caught it.

A better question than “is hormone therapy good or bad” is this: for whom, starting when, in what formulation, and for what specific symptom?

What Hormone Therapy Actually Does in Your Body

Menopausal hormone therapy typically means one of two things: estrogen alone, or estrogen combined with a progestogen.

Estrogen and progesterone aren’t interchangeable — they do genuinely different work in the body, and progesterone’s calming, sleep-supporting effect is separate from its role protecting the uterine lining. Source: author

Estrogen’s most direct effect is on the hypothalamus’s thermoregulatory center, which is why replacing it reliably reduces hot flashes and night sweats — this is the best-established, most consistently reproduced effect in the entire literature.

Estrogen also maintains bone density by slowing osteoclast activity, supports vaginal and urinary tissue integrity, and appears to have effects on vascular and cognitive function, though those effects are more time-dependent and harder to isolate.

Progesterone’s classic role is endometrial protection: in a woman who still has a uterus, unopposed estrogen thickens the uterine lining and raises endometrial cancer risk, so progesterone is added specifically to prevent that.

But progesterone does something else that gets left out of most conversations entirely.

In the brain, progesterone is metabolized into allopregnanolone, a neurosteroid that acts as a positive allosteric modulator of the GABA-A receptor — the same receptor system targeted by benzodiazepines and drugs like zolpidem. In plain language, that means progesterone has a direct, measurable calming effect on the nervous system, separate from anything estrogen is doing. Human and animal EEG sleep studies have shown that progesterone increases non-REM sleep and shifts brain activity toward the slow-wave frequencies associated with deep, restorative sleep — effects mediated through this allopregnanolone pathway. Unlike a benzodiazepine, which forces sedation and tends to suppress slow-wave sleep, progesterone’s effect is closer to restoring a rhythm the brain has simply lost access to.

Here’s the misconception worth correcting.

Most people think of hormone therapy as one intervention treating one symptom. It’s closer to two distinct interventions, with two distinct mechanisms, bundled under one name — which is part of why lumping every formulation and every outcome into a single “is it safe” verdict has caused so much confusion.

What the Studies Show

The Original Trial: What WHI Actually Found

In 2002, the Women’s Health Initiative halted the arm of its trial testing oral conjugated equine estrogen plus medroxyprogesterone acetate, after data showed increased risk of breast cancer, coronary heart disease, stroke, and blood clots. The trial had enrolled 161,808 postmenopausal women; the group receiving combined hormone therapy had a mean age of 63.2 — more than a decade past the average age of menopause in the United States.

The original 2002 warning came from a trial studying women averaging age 63 — more than a decade past the point most women today are asking about hormone therapy. Source: author

The findings were real, and the headlines that followed covered them as a blanket verdict on hormone therapy itself. Prescriptions fell 70 to 80 percent within a few years. What got lost in the coverage was the specificity of what had actually been tested: one formulation, one route of administration, in a population that was, on average, over a decade removed from the transition the therapy is primarily meant to treat.

So where does that leave the original alarm? It was a real signal in a specific population, generalized far past what the data supported.

Hormone therapy isn’t one uniform treatment. The original WHI warning applied to older women on oral CEE plus synthetic progestin; newer evidence and FDA guidance focus on timing and formulation for women closer to menopause. Source: author

The Reanalysis: The Timing Hypothesis

In the years since, researchers went back through WHI data and stratified outcomes by age at initiation and time since menopause — a lens the original trial design didn’t emphasize.

What emerged is often called the timing hypothesis.

Hormone therapy started within ten years of menopause carries a meaningfully different, generally more favorable risk-benefit profile than therapy started a decade or more later. A 2023 reappraisal published in *Maturitas (Stute P, Marsden J, Salih N, Cagnacci A. Maturitas.* 2023;174:8–13) concluded that hormone therapy appears to provide a better risk-benefit ratio when initiated closer to menopause onset, with symptomatic benefits outweighing cardiovascular and other risks in the short term.

This isn’t a fringe reinterpretation. It has become close to the mainstream position among menopause specialists, even as public perception has lagged badly behind it.

A 2024 review of WHI findings published in *JAMA (Manson JE, Crandall CJ, Rossouw JE, et al. JAMA.* 2024;331(20):1748–1760) explicitly supports hormone therapy initiation before age 60 for symptomatic women, while cautioning against using it specifically to prevent cardiovascular disease or dementia. The limitation is real: the timing-hypothesis evidence comes largely from reanalysis and observational data, not a new randomized trial designed around timing from the start. So how do we reconcile a landmark trial with its own reanalysis? By treating age and timing as central variables, not footnotes.

Conceptual curve showing more favorable overall risk–benefit when hormone therapy is started within about 10 years of menopause. Sources: WHI 2023 reappraisal published in Maturitas. Source: author

The Follow-Up Trials: KEEPS and ELITE

If WHI raised the alarm, later trials helped clarify what the alarm did and did not mean. Two of the most important studies here are KEEPS and ELITE, because both looked more directly at timing and at women closer to the menopausal transition than the original WHI population.

KEEPS — the Kronos Early Estrogen Prevention Study — examined recently menopausal women and found that hormone therapy improved menopausal symptoms and some markers of quality of life without showing the same broad pattern of harm that shaped public fear after WHI. Importantly, it studied women much closer to the age at which hormone therapy is actually considered in practice, which makes its relevance very different from a trial with an average starting age in the sixties.

ELITE — the Early versus Late Intervention Trial with Estradiol — went a step further by directly testing the timing hypothesis. It found that estradiol slowed the progression of subclinical atherosclerosis when started within six years of menopause, but not when started ten or more years later. That doesn’t mean hormone therapy should be prescribed as a cardiovascular prevention drug, but it strongly supports the idea that vascular response depends on when therapy begins.

What the Follow-Up Trials Actually Showed — KEEPS and ELITE clarified what WHI couldn’t: timing of hormone therapy initiation changes everything. Sources: Harman et al. Ann Intern Med 2014 · Gleason et al. PLOS Med 2015 · Hodis et al. NEJM 2016 · Source: author

These trials did not “erase” WHI. They refined it.

Together, they helped shift the field away from the simplistic idea that hormone therapy has one fixed safety profile and toward the much more defensible position that age, timing, formulation, and route all materially affect outcome.

That is a much less dramatic message than a black-box warning, but it is closer to the truth patients actually need.

Regulatory Guidance Now: What Changed in 2025 and 2026

On November 10, 2025, the FDA announced it would begin removing the boxed warning — its strongest safety label — from hormone therapy products, following a comprehensive literature review, an expert panel convened July 17, 2025, and a 60-day public comment period.

The agency’s stated reasoning echoed the timing-hypothesis critique directly: the average WHI participant was 63, while the average age of menopause in the United States is 51, meaning the population that drove the original warning didn’t resemble the population most likely to start therapy for symptom relief today.

The FDA’s actions included removal of boxed warning language referencing cardiovascular disease, breast cancer, and probable dementia; removal of the “lowest effective dose for the shortest duration” mandate; and addition of guidance supporting hormone therapy initiation in women under 60 or within 10 years of menopause for bothersome vasomotor symptoms. The agency did not remove the separate warning about endometrial cancer risk for estrogen-only products used in women who still have a uterus — that risk remains real and formulation-independent, which is exactly why progesterone or another progestogen still belongs in that specific situation regardless of this other change.

This is a significant, recent regulatory shift still unfolding. Individual product labels are being updated on a rolling per-product basis. Re-verify the specific product list and any further label changes if time has passed before this piece publishes.

Short-Term Trials: Progesterone and Sleep Specifically

Separate from the estrogen-focused WHI conversation, a 2023 randomized, double-blind, placebo-controlled trial tested 300 mg oral micronized progesterone at bedtime in 189 perimenopausal women with a mean age of 49.9 years. (Prior JC, Cameron A, Fung M, Hitchcock CL, Janssen P, Lee T, Singer J. Sci Rep. 2023;13:9082.)

The trial’s primary measured outcome — a daily symptom calendar tracking hot flash and night sweat frequency — did not show a statistically significant difference between groups (p=0.222).

But the secondary outcomes were more telling: women taking progesterone reported significantly improved sleep quality (p=0.005), significantly less perceived night sweat severity (p=0.023), and significantly less interference with daily life (p=0.017), with no increase in depression and no serious adverse events.

That distinction matters, and I want to be careful not to overclaim: the trial didn’t prove that progesterone eliminates hot flashes when you measure symptoms directly. What it did show was a meaningful, statistically significant improvement in sleep and daily functioning — which is often what perimenopausal patients come in asking for

So how do we reconcile a null primary outcome with a positive lived-experience result?

Carefully, and by naming both, rather than citing only the flattering half.

Why Studies Don’t All Agree

Several real variables explain why the hormone therapy literature looks so inconsistent from the outside.

Formulation is the biggest one.

Oral estrogen passes through the liver on first metabolism, which increases clotting factor production; transdermal estrogen largely bypasses that effect, which is why studies consistently show lower blood clot and stroke risk with patches or gels compared to pills. Synthetic progestins, particularly medroxyprogesterone acetate, carry androgenic activity that natural micronized progesterone doesn’t share, which appears to explain much of the difference in cardiovascular and breast tissue effects between the two.

A 2016 systematic review and meta-analysis (Asi N, et al. Systematic Reviews. 2016;5:121) found a relative risk for breast cancer of 0.67 with natural progesterone compared to synthetic progestins, when each was paired with estrogen.

In a systematic review and meta-analysis, estrogen paired with natural micronized progesterone showed a lower relative breast cancer risk than estrogen paired with a synthetic progestin. Source: author

Age and timing compound these formulation differences in ways the original WHI analysis obscured.

A healthy, recently menopausal 52-year-old starting therapy for hot flashes is not the same population as a 68-year-old with existing cardiovascular risk factors starting therapy for the first time, even though both could have been enrolled in the same WHI arm.

What gets measured also shapes what studies appear to show.

A trial recording objective hot flash frequency on a daily calendar is asking a different question than a trial measuring perceived sleep quality or quality of life — both are valid, but they don’t always move together, as the 2023 progesterone trial itself demonstrated.

Your friend’s experience on a particular regimen may look nothing like yours, even at a similar age, because the formulation, the route, the timing, and what’s being tracked can all diverge, sometimes sharply.

Who Should Be Careful with Hormone Therapy?

A few groups need real caution, and the recent regulatory softening doesn’t change that.

Women with a personal history of breast cancer, particularly hormone-receptor-positive disease, generally should not start systemic hormone therapy without close coordination with their oncologist. This population was not the focus of the recent labeling changes, and the calculus for them is different.

Women with unexplained vaginal bleeding need that investigated before hormone therapy is considered, since therapy can mask or delay diagnosis of an underlying uterine problem.

Women with a personal history of blood clots, stroke, or active liver disease need individualized evaluation, and oral estrogen in particular deserves extra scrutiny in this group given its effect on clotting factors. Transdermal routes are often the more appropriate starting point here.

And any woman with a uterus taking estrogen needs a progestogen alongside it, full stop — the endometrial cancer risk from unopposed estrogen is real, well-documented, and unaffected by anything discussed above. Skipping the progesterone because “the black box warning got removed” is a misreading of what actually changed.

Absolute vs. Relative Risk: The Part Most Headlines Never Explained

One of the biggest reasons hormone therapy still scares women is that most of the public conversation used relative risk headlines without giving absolute numbers. A phrase like “26 percent higher breast cancer risk” sounds enormous in isolation, but relative risk without baseline context can make a modest absolute increase feel catastrophic.

This is where the original WHI coverage did real damage.

In the estrogen-plus-progestin arm, the increased breast cancer risk translated to a small number of additional cases per 10,000 women per year, not an across-the-board inevitability for every woman considering treatment. That does not make the signal meaningless, but it does change how a rational person weighs symptom relief against risk.

The same principle matters in the other direction too.

If a woman is sleeping four fragmented hours a night, waking drenched in sweat, and watching her quality of life collapse, the cost of untreated symptoms is not zero. Good risk counseling is not “hormones are safe” or “hormones are dangerous.” It is a clear comparison between the absolute size of a risk, the formulation being used, the age and timing of initiation, and the severity of the symptoms being treated.

This is also why formulation-specific counseling matters so much.

The public inherited one generalized fear from one older oral regimen, then applied it to patches, gels, estradiol, and micronized progesterone as if they all carried identical risk. They do not. A woman deserves to hear her actual risk profile explained in absolute terms, not just emotionally loaded percentages.

Where Hormone Therapy Fits in a Longevity-Focused Lifestyle

Hormone therapy is not a replacement for the fundamentals, and it works better alongside them than instead of them.

Sleep architecture responds to more than progesterone alone.

Consistent sleep and wake times, limiting alcohol in the hours before bed, and keeping the bedroom genuinely dark and cool all support the same slow-wave sleep that progesterone is working to restore. Treating one lever while ignoring the others usually produces a partial result.

Movement matters for the same bone density and cardiovascular outcomes that hormone therapy is sometimes credited or blamed for.

Weight-bearing exercise and resistance training reduce fracture risk independent of hormone status, and they’re not optional just because a patient has started therapy.

Stress and autonomic balance connect directly to how symptoms are experienced.

Chronic stress elevates cortisol in ways that can worsen hot flash frequency and further disrupt sleep, independent of estrogen and progesterone levels — part of why two women on an identical hormone regimen can report very different symptom relief.

A realistic version of this, for a patient in her early fifties: consistent bedtime, a short walk most days, resistance training twice a week, alcohol limited to occasional rather than nightly, and hormone therapy as one well-chosen piece of a larger pattern rather than the entire plan.

What I Recommend in Clinic

If you’re generally healthy, within ten years of menopause, and dealing with hot flashes, night sweats, or perimenopausal sleep disruption, hormone therapy is worth a real conversation with your physician rather than something to rule out by default. Transdermal estradiol paired with oral micronized progesterone, taken at bedtime, is where I typically start that conversation, given the formulation-specific safety data discussed above.

If you have a personal history of breast cancer, blood clots, stroke, or active liver disease, this isn’t a self-directed decision. Bring it to a specialist who can weigh your specific history, and expect a more conservative starting point or a different approach entirely.

If your main complaint is sleep rather than hot flashes, and your standard labs look “normal,” ask specifically about a hormone panel that includes progesterone relative to estrogen, not just TSH and estradiol.

This is precisely the gap that leaves patients like Meera undiagnosed for years.

Distinguish the formulation before you distinguish whether to start at all. Oral versus transdermal estrogen, and micronized progesterone versus a synthetic progestin, are not interchangeable choices, and the data increasingly says the difference matters as much as the decision to treat in the first place.

If you remember nothing else, remember this: the 2002 warning was real, but it described one formulation in one population at one point past menopause. It was never the final word on hormone therapy as a whole, and the last several years of regulatory and research catch-up are finally saying so.

So, Is Hormone Therapy Good or Bad?

For most women within about ten years of menopause, dealing with real vasomotor or sleep symptoms, hormone therapy — chosen with attention to formulation — is a reasonable, evidence-supported option, not the reckless choice two decades of headlines implied.

For women further past menopause, or with a personal history of breast cancer, clotting disorders, or unexplained bleeding, real caution remains appropriate, and nothing about the recent regulatory changes erases that.

For everyone else caught in between — carrying twenty years of inherited fear about a study most of them never read — the honest answer is close to what should have been said from the beginning: this isn’t a single treatment with a single verdict.

It depends on who you are, what you’re taking, and when you started.

Good labs. Bad life.

There’s a reason, and sometimes the reason is a hormone nobody thought to check, sitting quietly behind a decades-old headline that outlived its own data.

The Biology Is Biography series examines one health question at a time — without the hype in either direction.

For deeper clinical essays on what medicine often misses and what patients actually feel, subscribe to my Substack: Healing the Split. For readers who want more than a test result or a yes/no verdict.

More from Biology Is Biography

Is Heart Rate Variability Actually Useful, or Just Another Wellness Number to Obsess Over?

If you’d like to explore more of my work, these are good places to start:

Latest

• Are Peptide Injections Safe? A Bodybuilder‑Physician Explains

Longevity & Aging

• I’m a Longevity Physician, and I Do These 3 Overlooked Things Every Morning to Slow Aging
• Your Hormones Are Aging Faster Than You Think — Here’s What to Do About It

Weight Loss, Metabolism & Physiology

• Loose Skin After Weight Loss: What Actually Works, From an MD
• I’m a 47‑Year‑Old Physician/Athlete. Here Are 7 Things I’d Never Do for Fat Loss Again
• I Built My Best Body at 45 — Here’s What Every Middle‑Aged Athlete Gets Wrong About Metabolism
• You’re Not Lazy — Your Cardio Plan Is Just Wrong

About the Author

Dr. Shiv Kumar Goel is a board-certified physician practicing internal, functional, and aesthetic medicine in San Antonio, Texas. He is the founder of Prime Vitality Care and TimeVitality.ai — an AI venture bridging East-West medicine with precision diagnostics. He brings over two decades of clinical experience to the intersection of conventional diagnostics and the lived reality of patients whose suffering resists easy measurement.

He is the author of What Medicine Misses and Patients Feel & Healing the Split: When Your Biology Is Fighting Your Biography (forthcoming) — a physician’s account of the gap between clinical measurement and lived patient experience.

His work appears in Biology Is Biography (Medium’s In Fitness And In Health), Life Beyond Labs (Medium’s Illumination), and on his Substack, Healing the Split.

To follow his work: drshivgoel.com.

To reach him directly: contact@drshivgoel.com

Sources

1. Writing Group for the Women’s Health Initiative Investigators (Rossouw JE, Anderson GL, Prentice RL, et al.). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
2. Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542.
3. Stute P, Marsden J, Salih N, Cagnacci A. Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice. Maturitas. 2023;174:8–13. doi:10.1016/j.maturitas.2023.04.271.
4. U.S. Food and Drug Administration. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. November 10, 2025. FDA.gov. [Expert panel July 17, 2025; 60-day public comment period. Labeling updates rolling per-product — re-verify before publication.]
5. Prior JC, Cameron A, Fung M, Hitchcock CL, Janssen P, Lee T, Singer J. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a Phase III Canada-wide randomized placebo-controlled 4-month trial. Sci Rep. 2023;13:9082. doi:10.1038/s41598–023–35826-w.
6. Asi N, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Systematic Reviews. 2016;5:121. doi:10.1186/s13643–016–0294–5. [RR 0.67, 95% CI 0.55–0.81.]
7. Newson LR, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. Br J Gen Pract. 2018;68(675):499–500. doi:10.3399/bjgp18X699353.
8. Friess E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R. Progesterone-induced changes in sleep in male subjects. Am J Physiol Endocrinol Metab. 1997;272(5 Pt 1):E885-E891. doi:10.1152/ajpendo.1997.272.5.E885. [Human study, male subjects.]
9. Lancel M, Faulhaber J, Holsboer F, Rupprecht R. Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol Endocrinol Metab. 1996;271(4 Pt 1):E763-E772. doi:10.1152/ajpendo.1996.271.4.E763. PMID: 8897866. [Rat study; allopregnanolone/GABA-A mechanism.]
10. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249–260. doi:10.7326/M14–0353.
11. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS–Cognitive and Affective Study. PLOS Med. 2015;12(6):e1001833. doi:10.1371/journal.pmed.1001833.
12. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221–1231. doi:10.1056/NEJMoa1505241.